Tigecycline - PureIMS/Radboud University Nijmegen Medical Centre
Latest Information Update: 08 Sep 2023
At a glance
- Originator Radboud University Nijmegen Medical Centre
- Developer PureIMS; Radboud University Nijmegen Medical Centre
- Class Antibacterials; Glycylcyclines; Small molecules
- Mechanism of Action Mitochondrial protein inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Nontuberculous mycobacterium infections
Most Recent Events
- 07 Jul 2021 PureIMS, Sever Pharma Solutions and Radboud University Nijmegen Medical Centre enter into an agreement to develop inhaled formulation of tigecycline (Radboud University Nijmegen Medical Centre website, July 2023)
- 07 Jul 2021 Early research in Nontuberculous mycobacterium infections in Netherlands (Inhalation) (Radboud University Nijmegen Medical Centre website, July 2023) (PureIMS pipeline, July 2023)